Actinogen Medical (ACW) investor relations material

Executive summary

• XanaMIA pivotal Phase 2b/3 Alzheimer’s trial completed its last patient visit in late September; topline results remain on track for November 2026.

• September-quarter cash was $15.9m; including expected net R&D tax rebate proceeds of ~ $6m, pro forma cash is ~ $21.9m, with runway to late CY2027 or into CY2028 if new trials are substantially partnership-funded.

Financial highlights

• Net operating cash outflow was $6.206m for the September quarter; R&D payments were $4.332m and administration and corporate costs were $1.641m.

• Cash and cash equivalents ended the quarter at $15.865m, down from $16.735m at the start of the period.

• Net financing cash inflow was $5.336m, including $4.566m from option exercises and $987k from equity issues, less $217k in transaction costs.

Outlook and guidance

• Topline XanaMIA results are expected in November 2026; preparations are underway for regulatory engagement and a potential final pivotal AD trial if results are positive.

• Cash runway is forecast to extend to late CY2027 or into CY2028, assuming new trials are substantially funded through partnerships; trial-related cash burn is expected to abate as final invoices are settled.

• Up to $22.5m may be received from listed option exercises, with expiry dates in May and September 2027.